Get the Stockscreener App
4.35
5.58%
0.23
After Hours:
4.32
-0.03
-0.69%
Perspective Therapeutics Inc stock is traded at $4.35, with a volume of 1.39M.
It is up +5.58% in the last 24 hours and down -63.35% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$4.12
Open:
$4.15
24h Volume:
1.39M
Relative Volume:
0.98
Market Cap:
$294.01M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-53.31
EPS:
-0.0816
Net Cash Flow:
$-37.99M
1W Performance:
+25.36%
1M Performance:
-63.35%
6M Performance:
-67.78%
1Y Performance:
+74.00%
1-Day Range:
$4.15
$4.52
1-Week Range:
$3.48
$4.64
52-Week Range:
$2.28
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.35 | 294.01M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
118.77 | 206.00B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
392.15 | 149.49B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
90.66 | 133.62B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
86.54 | 110.97B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.35 | 42.08B | 6.60B | 4.16B | 490.10M | 6.93 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock - Investing.com India
Perspective Therapeutics selloff a buying opportunity, says JonesResearch - MSN
Insider Buying: Jonathan Hunt Acquires Shares of Perspective The - GuruFocus.com
Perspective Therapeutics director Robert Williamson acquires shares worth $22,813 - Investing.com
Jonathan Robert Hunt Acquires 12,829 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock - MarketBeat
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December - The Manila Times
Perspective Therapeutics to Present at Piper and Evercore Healthcare Conferences in December | CATX Stock News - StockTitan
Perspective Therapeutics price target lowered to $9 from $17 at B. Riley - TipRanks
Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 14,500 Shares - MarketBeat
Perspective Therapeutics CEO Johan Spoor buys $100,468 in stock - Investing.com
Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital - Yahoo Finance
Perspective Therapeutics downgraded to Neutral from Buy at BofA - Yahoo Finance
Perspective Therapeutics (NYSE:CATX) Price Target Cut to $16.00 by Analysts at Oppenheimer - Defense World
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock faces challenges, opportunities - Investing.com
Perspective Therapeutics shares hold Outperform as RBC adjusts expectations for progress - Investing.com Nigeria
Bank of America Downgrades Perspective Therapeutics (NYSE:CATX) to Neutral - MarketBeat
Autonomix Medical (NASDAQ:AMIX) vs. Perspective Therapeutics (NYSE:CATX) Critical Review - Defense World
Perspective Therapeutics stock downgraded to Neutral By Investing.com - Investing.com Nigeria
Perspective Therapeutics stock downgraded to Neutral - Investing.com India
Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer - TipRanks
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Stock market news: SKK Holdings Limited declined by 51.53% while SCWorx Corp. surged by 101.02% during mid day trading - Business Upturn
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings - Benzinga
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Perspective stock slips after radio pharma data (CATX:NYSE) - Seeking Alpha
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium - The Manila Times
Cantor Fitzgerald Has Positive View of CATX FY2024 Earnings - MarketBeat
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 - The Manila Times
Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Avidity Partners Management LP Bolsters Portfolio with Perspecti - GuruFocus.com
Analysis of COMMODORE CAPITAL LP's Recent Transaction in Perspec - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Janus Henderson Group PLC Increases Stake in Perspective Therape - GuruFocus.com
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's potential in focus By Investing.com - Investing.com South Africa
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's potential in focus - Investing.com
Perspective Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Perspective Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
Perspective Therapeutics Inc (CATX) Shares Down 4.92% on Nov 13 - GuruFocus.com
Perspective Therapeutics Reports Strong Cash Position and Clinical Advances - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results - The Manila Times
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) - Benzinga
WealthPlan Investment Management LLC Purchases New Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
FMR LLC Acquires Shares in Perspective Therapeutics Inc - GuruFocus.com
Lantheus Reports Third Quarter 2024 Financial Results - The Manila Times
Perspective Therapeutics, Inc. (NYSE:CATX) Receives $20.63 Consensus Price Target from Analysts - MarketBeat
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.73%
0.14%
Cap:
|
Volume (24h):